Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients9

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients5

Views

Views
May 20242
June 20240
July 20243
August 20240
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
 

Top cities views

Views
Chicago1
DeKalb1
Prineville1